Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 136

Sort by

Sort Order Select

Journal Articles

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Blood (2025) 146 (22): 2629–2640.

https://doi.org/10.1182/blood.2025029909

Published: 2025

Includes: Supplemental data

Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Nirav Shah, Scott Huntington, David Lewis, Talha Munir, Graham Collins, Alvaro Alencar, Kim Linton, Zulfa Omer, Dima El-Sharkawi, Mary Gleeson, Pamela McKay, Jeanette Doorduijn, Jeffery Smith, Daniel Morillo, Pau Abrisqueta, Sarah Injac, Astrid Pulles

Blood (2025) 146 (Supplement 1): 5359.

https://doi.org/10.1182/blood-2025-5359

Published: 2025

Journal Articles

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Ana Marin Niebla, Eva Gine, Mariana Bastos-Oreiro, Amanda Perez, Alba Cabirta, Fatima De la Cruz Vicente, Marta Canelo Vilaseca, Ana Jiménez Ubieto, Sonia González De Villambrosia, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Pilar Gomez Prieto, Raul Cordoba, Ana Saus Carreres, Alejandro Martin Garcia-Sancho, Ana Maria Garcia-Noblejas Moya, Carlos Grande, Pablo Prieto Martínez, Concepción Nicolás, Antonio Gutierrez, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Maria Teresa Villalobos, Tomas García-Cerecedo, Rosalia Alonso Trillo, Eva Donato, Paola Villafuerte Gutiérrez, Daniel García Belmonte, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Juan-Manuel Sancho, Beatriz De La Cruz, Raja Prince-Eladnani, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2025-3592

Published: 2025

Journal Articles

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez, Ana Saus Carreres, Sonia González De Villambrosia, Marta Canelo, Ana Maria Garcia-Noblejas Moya, Beatriz De La Cruz Benito, Paola Villafuerte Gutiérrez, Fatima De la Cruz Vicente, Juan Carlos Caballero, Ana Jiménez-Ubieto, Daniel García Belmonte, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Alejandro Martin Garcia-Sancho, Carlos Grande, Concepción Nicolás, Antonio Gutierrez, Marina Gomez-Llobell, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Ainara Ferrero Campos, Rosalia Alonso Trillo, Eva Donato, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Pilar Gomez Prieto, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Raul Cordoba, Juan-Manuel Sancho, Eva Gine, Víctor Navarro Garces, Pau Abrisqueta, Ana Marin Niebla

Blood (2025) 146 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2025-3585

Published: 2025

Journal Articles

Longitudinal immune dynamics associated with chronic lymphocytic leukemia development in mice with 13q14 deletion and modulation by early BTK inhibition

Patricia Fernández-Guzmán, Iñaki Salvador Corres, Hristo Iliev Iliev, Gemma Pujadas Rovira, Víctor Navarro Garces, Anna Aguilera Romero, Josep Castellvi, Daniel Medina-Gil, Maite Erguin, Sofia Mallorquí-Alcalá, Angel Serna, Pau Abrisqueta, Francesc Bosch Albareda, Marta Crespo

Blood (2025) 146 (Supplement 1): 5656.

https://doi.org/10.1182/blood-2025-5656

Published: 2025

Journal Articles

Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry

Blood (2025) 146 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2025-1233

Published: 2025

Journal Articles

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

Mariana Bastos-Oreiro, Gloria Iacoboni, Pablo Manresa, Carolina Martinez, Laura Magnano, Ana Jiménez Ubieto, Sofía Vázquez-Díaz, Maria Jose Rodriguez Salazar, Maria Teresa Busnego Barreto, Raquel Del Campo, Pedro José Paúl Vidaller, Ilda Murillo, Eva Donato, Angel Serna, Hugo Daniel Luzardo Henríquez, Pilar Gomez Prieto, Elena Perez Ceballos, Begona Mendibil, Sergio Ramons, Ana Maria Garcia-Noblejas Moya, Sonia González De Villambrosia, Francisco Javier Diaz Galvez, Javier Lopez Jimenez, Paula Fernandez-Caldas, Antonio Gutierrez, Blanca Sanchez, Nazaret Dominguez, María Civeira Marin, Paola Villafuerte Gutiérrez, Izaskun Zeberio, Irati Ormezabal, Cristina Barrenetxea Lekue, Norma Gutiérrez, Sofia Martin-Consuegra, Samuel Romero Dominguez, Sofia Huerga, Nuria Golbano, Rosalia Riazza, Jose Antonio Hueso García, Pilar Martinez-Barranco, Belen Navarro Matilla, Lucia Villalon Blanco, Paula Ortega Nadal, Ana Torres Tienza, Víctor Navarro Garces, Pau Abrisqueta, Alejandro Martin Garcia-Sancho

Blood (2025) 146 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2025-2732

Published: 2025

Journal Articles

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Blood (2025) 146 (Supplement 1): 66.

https://doi.org/10.1182/blood-2025-66

Published: 2025

Journal Articles

The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma

Sergi Camarillas, Samantha Feijoo, Anna Aguilera Romero, Corrado Benevolo Savelli, Víctor Navarro Garces, Andreu Vilaseca, Maria Landwehr, Helena Ariño, Marina Serra, Marc Bosch-Schips, Cristina García Herce, Cecilia Carpio, Mario Sánchez-Salinas, Alfredo Rivas-Delgado, Pau Abrisqueta, Francesc Bosch Albareda, Pere Barba, Gloria Iacoboni

Blood (2025) 146 (Supplement 1): 5498.

https://doi.org/10.1182/blood-2025-5498

Published: 2025

Journal Articles

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2025-5497

Published: 2025

Journal Articles

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

Angel Serna, Gloria Iacoboni, Anna Aguilera Romero, Victor Navarro, Carolina Martinez, Pablo Manresa, Laura Magnano, Ana Jiménez Ubieto, Sofía Vázquez-Díaz, Maria Jose Rodriguez Salazar, Maria Teresa Busnego Barreto, Raquel Del Campo, Pedro José Paúl Vidaller, Ilda Murillo, Eva Donato, Hugo Daniel Luzardo Henríquez, Pilar Gomez Prieto, Elena Perez Ceballos, Begona Mendibil, Sergio Ramos, Ana Maria Garcia-Noblejas Moya, Sonia González De Villambrosia, Francisco Javier Diaz Galvez, Javier Lopez Jimenez, Paula Fernández-Caldas, Ruben Fernandez Alvarez, Antonio Gutierrez, Blanca Sanchez, Nazaret Dominguez, María Civeira Marin, Paola Villafuerte Gutiérrez, Iñigo Olazabal, Izaskun Zeberio, Cristina Barrenetxea Lekue, Diego Clavo-Martín, Samuel Romero Dominguez, Sofia Martin-Consuegra, Sofia Huerga, Nuria Golbano, Rosalia Riazza, Jose Antonio Hueso García, Pilar Martinez-Barranco, Belen Navarro Matilla, Lucia Villalon Blanco, Paula Ortega Nadal, Ana Torres Tienza, Alejandro Martin Garcia-Sancho, Mariana Bastos-Oreiro, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3737.

https://doi.org/10.1182/blood-2025-3737

Published: 2025

Journal Articles

Impact of extranodal involvement on bispecific antibody (BsAb) outcomes in patients with large B-cell lymphoma (LBCL)

Blood (2025) 146 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2025-1962

Published: 2025

Journal Articles

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

Blood (2025) 146 (Supplement 1): 782.

https://doi.org/10.1182/blood-2025-782

Published: 2025

Journal Articles

ST2 as a biomarker of cytokine release syndrome following CD19-targeted chimeric antigen receptor T-cell therapy

Guillermo Orti, Cecilia Carpio, Gloria Iacoboni, Lorenzo Carita, Samantha Feijoo, Corrado Benevolo Savelli, Mario Sánchez-Salinas, Alfredo Rivas-Delgado, Víctor Navarro Garces, Sergi Cantenys-Molina, Monica Martinez, Miguel Gonzalez, Marta Crespo, Pau Abrisqueta, Francesc Bosch Albareda, Pere Barba

Blood (2025) 146 (Supplement 1): 2365.

https://doi.org/10.1182/blood-2025-2365

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7

Lori Leslie, Gerardo Musuraca, Pau Abrisqueta, Joshua Brody, Jacob Christensen, Alexander Fosså, Marjolein Van Der Poel, Joost Vermaat, Fritz Offner, David Belada, Jian Mei, Isil Altintas, Malene Risum, Aidan Reilly, Liwei Wang, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 465.

https://doi.org/10.1182/blood-2025-465

Published: 2025

Journal Articles

Immune Crosstalk Profiling of Non-Hodgkin Lymphoma (NHL) Tumor Immune Microenvironment Identifies Two Clusters Based on T Cell Exhaustion, Correlating with Different Clinical Outcomes

Daniel Medina, Laura Palomo, Víctor Navarro, Cristina García, Juan Camilo Nieto, Júlia Carabia, Carlota Pagès Geli, Pamela Acha, Gemma Pujadas, Carlos Palacio, Laura Gallur, Josep Castellvi, Pau Abrisqueta, Francesc Bosch, Marta Crespo

Blood (2024) 144 (Supplement 1): 6251.

https://doi.org/10.1182/blood-2024-205108

Published: 2024

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Longitudinal immune dynamics associated with chronic lymphocytic leukemia development in mice with 13q14 deletion and modulation by early BTK inhibition

Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

Impact of extranodal involvement on bispecific antibody (BsAb) outcomes in patients with large B-cell lymphoma (LBCL)

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

ST2 as a biomarker of cytokine release syndrome following CD19-targeted chimeric antigen receptor T-cell therapy

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7

Immune Crosstalk Profiling of Non-Hodgkin Lymphoma (NHL) Tumor Immune Microenvironment Identifies Two Clusters Based on T Cell Exhaustion, Correlating with Different Clinical Outcomes

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only